Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway
- PMID: 29571014
- DOI: 10.1016/j.biopha.2018.03.071
Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway
Abstract
Objective: This study aimed to investigate the antitumor effects and possible regulatory mechanisms of sanguinarine in epithelial ovarian cancer.
Material and methods: The effects of sanguinarine on the malignant behaviors of epithelial ovarian cancer SKOV3 cells and the expression of long non-coding RNA CASC2 were investigated. The expression of CASC2 and EIF4A3 in epithelial ovarian cancer tissues and cells were detected, and the potential mechanisms of sanguinarine were explored by investigating the interactions between CASC2 and EIF4A3. Furthermore, the regulatory relationship between sanguinarine and nuclear factor-κB (NF-κB) signaling or PI3K/AKT/mTOR pathway was explored.
Results: Sanguinarine exhibited antitumor effects in SKOV3 cells by significantly inhibiting cell viability, migration and invasion and promoting cell apoptosis. Moreover, sanguinarine induced CASC2 expression and silencing of CASC2 reversed the effects of sanguinarine in epithelial ovarian cancer cells. CASC2 was significantly lowly expressed in ovarian cancer tissues and cells, while EIF4A3 was highly expressed. EIF4A3 was identified as a CASC2 binding protein. Knockdown of EIF4A3 reversed the effects of sanguinarine plus CASC2 silencing. Besides, sanguinarine markedly inhibited the activation of NF-κB signaling or PI3K/AKT/mTOR pathway, which was reversed by CASC2 silencing. And the effects of sanguinarine plus CASC2 silencing on the activation of these pathways were further reversed after knockdown of EIF4A3 at the same time.
Conclusions: Our findings reveal that sanguinarine exhibits antitumor effects in epithelial ovarian cancer cells possible via regulating CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway. Sanguinarine may serve as a potential therapeutic reagent for epithelial ovarian cancer.
Keywords: EIF4A3; Long non-coding RNA CASC2; Nuclear factor-κB signaling; Ovarian cancer; PI3K/AKT/mTOR pathway; Sanguinarine.
Copyright © 2018. Published by Elsevier Masson SAS.
Similar articles
-
[Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].Zhonghua Fu Chan Ke Za Zhi. 2012 Feb;47(2):134-8. Zhonghua Fu Chan Ke Za Zhi. 2012. PMID: 22455747 Chinese.
-
The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.Oncotarget. 2015 Sep 22;6(28):25520-32. doi: 10.18632/oncotarget.4550. Oncotarget. 2015. PMID: 26267321 Free PMC article.
-
Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells In Vitro and In Vivo through Inhibiting the PI3K/AKT/mTOR/NF-κB Signaling Pathway.Biomed Res Int. 2022 Mar 2;2022:5739909. doi: 10.1155/2022/5739909. eCollection 2022. Biomed Res Int. 2022. PMID: 35281608 Free PMC article.
-
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22. Semin Cancer Biol. 2019. PMID: 31128298 Review.
-
MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance.J Cancer Res Clin Oncol. 2018 Dec;144(12):2313-2318. doi: 10.1007/s00432-018-2737-y. Epub 2018 Aug 14. J Cancer Res Clin Oncol. 2018. PMID: 30109500 Review.
Cited by
-
Identification and Validation of an 11-Ferroptosis Related Gene Signature and Its Correlation With Immune Checkpoint Molecules in Glioma.Front Cell Dev Biol. 2021 Jun 23;9:652599. doi: 10.3389/fcell.2021.652599. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 34249910 Free PMC article.
-
Long Non-coding RNA CASC2 Enhances the Antitumor Activity of Cisplatin Through Suppressing the Akt Pathway by Inhibition of miR-181a in Esophageal Squamous Cell Carcinoma Cells.Front Oncol. 2019 May 7;9:350. doi: 10.3389/fonc.2019.00350. eCollection 2019. Front Oncol. 2019. PMID: 31134151 Free PMC article.
-
LncRNA CASC2 Inhibits Progression of Glioblastoma by Regulating the Expression of AKT in T98G Cell Line, Treated by TMZ and Thiosemicarbazone Complex.Asian Pac J Cancer Prev. 2023 May 1;24(5):1553-1560. doi: 10.31557/APJCP.2023.24.5.1553. Asian Pac J Cancer Prev. 2023. PMID: 37247274 Free PMC article.
-
Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.Cell Cycle. 2020 Dec;19(23):3277-3288. doi: 10.1080/15384101.2020.1839700. Epub 2020 Oct 30. Cell Cycle. 2020. PMID: 33121324 Free PMC article.
-
Knockdown of LncRNA PANDAR by CRISPR-dCas9 Decreases Proliferation and Increases Apoptosis in Oral Squamous Cell Carcinoma.Front Mol Biosci. 2021 Mar 26;8:653787. doi: 10.3389/fmolb.2021.653787. eCollection 2021. Front Mol Biosci. 2021. PMID: 33842552 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous